| Literature DB >> 32821354 |
Mark Kilongosi Webale1, Christine Wanjala2, Bernard Guyah3, Nathan Shaviya2, Godwil O Munyekenye1, Peter Lokamar Nyanga4, Immaculate Nyaseba Marwa1, Sammy Kagoiyo1, Laura Nyawira Wangai1, Sella K Webale3, Kenny Kamau1, Nicholas Kitungulu5.
Abstract
AIM: Determine the prevalence of enteric bacterial pathogens and their antimicrobial resistance among diarrheic children in Nairobi City, Kenya.Entities:
Keywords: Epidemiology; antimicrobial resistance; bacterial diarrhea
Year: 2020 PMID: 32821354 PMCID: PMC7417493
Source DB: PubMed Journal: Gastroenterol Hepatol Bed Bench ISSN: 2008-2258
Demographic and clinical information of study participants
| Characteristics | Number (%) |
|---|---|
| Age in months | |
| 1-36 | 242 (70.0) |
| 37-60 | 112 (30.0) |
| Gender | |
| Female | 181 (48) |
| Male | 193 (52) |
| Source of water | |
| Piped water | 371 (99.2) |
| Borehole | 3 (0.8) |
| Water treatment | 220 (58.8) |
| Occupation of guardian | |
| Health care practitioner | 2 (0.5) |
| Office/administrative/support | 17 (4.5) |
| Construction/installation/repair | 5 (1.3) |
| Education/ training | 14 (3.7) |
| Sales | 178 (47.6) |
| Unemployed | 158 (42.2) |
| Body temperature | |
| <38.0 | 58 (15.5) |
| ≥ 38.0 | 316 (84.5) |
| Duration of diarrhea | |
| 1-3 | 308 (82.4) |
| 4-6 | 35 (9.4) |
| ≥7 | 31 (8.3) |
| Symptoms | |
| Vomiting | 298 (79.7) |
| Fever | 310 (82.9) |
| Abdominal cramp | 251 (67.1) |
| Headache | 12 (3.2) |
| Nausea | 50 (13.4) |
| Appetite loss | 345 (92.2) |
| Sunken eyeballs | 311 (83.2) |
| Dry tongue | 117 (31.3) |
| Reduced skin elasticity | 192 (51.3) |
Data are presented as number and proportions (%) of study participants. ≤, less than or equal to. <, less than. ≥, greater than or equal to. >, greater than.
Prevalence of enteric bacterial pathogens isolated from study participants
| Enteropathogenic bacteria | N (%) |
|---|---|
| Diarrheagenic | 136 (36.4) |
| EAEC | 78 (20.9) |
| EPEC | 15 (4.0) |
| ETEC | 38 (10.2) |
| EIEC | 2 (0.5) |
| EAEC/EPEC/ETEC | 1 (0.3) |
| EAEC/ETEC | 2 (0.5) |
|
| 9 (2.4) |
|
| 12 (3.2) |
|
| 2 (0.5) |
|
| 1 (0.3) |
|
| 7 (1.9) |
|
| 2 (0.5) |
|
| 6 (1.6) |
|
| 5 (1.3) |
|
| 4 (1.1) |
|
| 9 (2.4) |
| EAEC | 4 (1.1) |
| EAEC | 2 (0.5) |
| EAEC | 1 (0.3) |
| EPEC | 1 (0.3) |
| ETEC | 1 (0.3) |
Data are presented as number and proportions (%) of study participants. E. coli, Escherichia coli. EPEC, enteropathogenic E. coli. ETEC, enterotoxigenic E. coli. EAEC, enteroaggregative E. coli. EIEC, enteroinvasive E. coli.
Antimicrobial susceptibility patterns of enteric bacterial pathogens isolated from study participants
| Enterpathogenic bacteria | Antibiotic | Susceptibility pattern (%) | ||
|---|---|---|---|---|
| Sensitive | Intermediate | Resistant | ||
| Diarrheagenic | Ampicillin | 22 (15.2) | 43 (29.7) | 80 (55.2) |
| Trimethoprim/sulfamethoxazole | 25 (17.2) | 31 (21.4) | 89 (61.4) | |
| Ceftriaxone | 106 (73.1) | 21 (14.5) | 18 (12.4) | |
| Streptomycin | 34 (23.4) | 20 (13.8) | 91 (76.6) | |
| Amoxicillin/clavulanic acid | 87 (60.0) | 20 (13.8) | 38 (26.2) | |
| Gentamycin | 48 (33.1) | 28 (19.3) | 69 (47.6) | |
| Kanamycin | 10 (6.9) | 44 (30.3) | 91 (62.8) | |
| Ciprofloxacin | 94 (64.8) | 10 (6.9) | 41 (28.3) | |
| Chloramphenicol | 14 (9.7) | 41 (28.3) | 90 (62.1) | |
| Erythromycin | 81 (55.9) | 52 (35.9) | 12 (8.3) | |
| Nalidixic acid | 99 (68.3) | 30 (20.7) | 16 (11.0) | |
| Tetracycline | 15 (10.3) | 10 (6.9) | 120 (82.8) | |
|
| Ampicillin | 0 (0.0) | 2 (22.2) | 7 (77.8) |
| Trimethoprim/sulfamethoxazole | 9 (100.0) | 0 (0.0) | 0 (0.0) | |
| Ceftriaxone | 2 (22.2) | 0 (0.0) | 7 (77.8) | |
| Streptomycin | 0 (0.0) | 0 (0.0) | 9 (100.0) | |
| Amoxicillin/clavulanic acid | 4 (44.4) | 0 (0.0) | 5 (55.6) | |
| Gentamycin | 9 (100.0) | 0 (0.0) | 0 (0.0) | |
| Kanamycin | 1 (11.1) | 0 (0.0) | 8 (88.9) | |
| Ciprofloxacin | 0 (0.0) | 1 (11.1) | 8 (88.9) | |
| Chloramphenicol | 2 (22.2) | 0 (0.0) | 7 (77.8) | |
| Erythromycin | 1 (11.1) | 2 (22.2) | 6 (66.7) | |
| Nalidixic acid | 9 (100.0) | 0 (0.0) | 0 (0.0) | |
| Tetracycline | 3 (33.3) | 1 (11.1) | 5 (55.6) | |
|
| Ampicillin | 2 (9.5) | 6 (28.6) | 13 (28.6) |
| Trimethoprim/sulfamethoxazole | 8 (38.1) | 3 (14.3) | 10 (47.6) | |
| Ceftriaxone | 11 (52.4) | 0 (0.0) | 10 (47.6) | |
| Streptomycin | 2 (9.5) | 7 (33.3) | 12 (57.1) | |
| Amoxicillin/clavulanic acid | 16 (76.2) | 1 (4.8) | 4 (19.0) | |
| Gentamycin | 18 (85.7) | 1 (4.8) | 2 (9.5) | |
| Kanamycin | 4 (19.0) | 17 (81.0) | 0 (0.0) | |
| Ciprofloxacin | 11 (52.4) | 6 (28.6) | 4 (19.0) | |
| Chloramphenicol | 5 (23.8) | 4 (19.0) | 12 (57.1) | |
| Erythromycin | 5 (23.8) | 14 (66.7) | 2 (9.5) | |
| Nalidixic acid | 13 (62.0) | 4 (19.0) | 4 (19.0) | |
| Tetracycline | 4 (19.0) | 3 (14.3) | 14 (66.7) | |
|
| Ampicillin | 2 (33.3) | 1 (16.7) | 3 (50.0) |
| Trimethoprim/sulfamethoxazole | 5 (83.3) | 0 (0.0) | 1 (16.7) | |
| Ceftriaxone | 4 (66.7) | 1 (16.7) | 1 (16.7) | |
| Streptomycin | 5 (83.3) | 1 (16.7) | 0 (0.0) | |
| Amoxicillin/clavulanic acid | 6 (100.0) | 0 (0.0) | 0 (0.0) | |
| Gentamycin | 5 (83.3) | 0 (0.0) | 1 (16.7) | |
| Kanamycin | 4 (66.7) | 2 (33.3) | 0 (0.0) | |
| Ciprofloxacin | 6 (100.0) | 0 (0.0) | 0 (0.0) | |
| Chloramphenicol | 0 (0.0) | 1 (33.3) | 4 (66.7) | |
| Erythromycin | 1 (16.7) | 2 (33.3) | 3 (50.0) | |
| Nalidixic acid | 4 (66.7) | 2 (33.3) | 0 (0.0) | |
| Tetracycline | 1 (16.7) | 0 (0.0) | 5 (83.3) | |
|
| Ampicillin | 0 (0.0) | 0 (0.0) | 5 (100.0) |
| Trimethoprim/sulfamethoxazole | 2 (40.0) | 2 (40.0) | 1 (20.0) | |
| Ceftriaxone | 0 (0.0) | 4 (80.0) | 1 (20.0) | |
| Streptomycin | 0 (0.0) | 0 (0.0) | 5 (100.0) | |
| Amoxicillin/clavulanic acid | 3 (60.0) | 1 (20.0) | 1 (20.0) | |
| Gentamycin | 0 (0.0) | 0 (0.0) | 5 (100.0) | |
| Kanamycin | 1 (20.0) | 4 (80.0) | 0 (0.0) | |
| Ciprofloxacin | 5 (100.0) | 0 (0.0) | 0 (0.0) | |
| Chloramphenicol | 0 (0.0) | 1 (20.0) | 4 (80.0) | |
| Erythromycin | 0 (0.0) | 4 (80.0) | 1 (20.0) | |
| Nalidixic acid | 3 (60.0) | 2 (40.0) | 0 (0.0) | |
| Tetracycline | 1 (20.0) | 1 (20.0) | 3 (60.0) | |
| Enterpathogenic bacteria | Antibiotic | Susceptibility pattern (%) | ||
| Sensitive | Intermediate | Resistant | ||
|
| Ampicillin | 0 (0.0) | 3 (75.0) | 1 (25.0) |
| Trimethoprim/sulfamethoxazole | 2 (50.0) | 1 (25.0) | 0 (0.0) | |
| Ceftriaxone | 4 (100.0) | 0 (0.0) | 0 (0.0) | |
| Streptomycin | 2 (50.0) | 2 (50.0) | 0 (0.0) | |
| Amoxicillin/clavulanic acid | 4 (100.0) | 0 (0.0) | 0 (0.0) | |
| Gentamycin | 4 (100.0) | 0 (0.0) | 0 (0.0) | |
| Kanamycin | 3 (50.0) | 1(25.0) | 0 (0.0) | |
| Ciprofloxacin | 4 (100.0) | 0 (0.0) | 0 (0.0) | |
| Chloramphenicol | 0 (0.0) | 2 (50.0) | 2 (50.0) | |
| Erythromycin | 1 (25.0) | 3 (75.0) | 0 (0.0) | |
| Nalidixic acid | 4 (100.0) | 0 (0.0) | 0 (0.0) | |
| Tetracycline | 0 (0.0) | 1 (25.0) | 3 (75.0) | |
| Kanamycin | 4 (19.0) | 17 (81.0) | 0 (0.0) | |
| Nalidixic acid | 3 (60.0) | 2 (40.0) | 0 (0.0) | |
| Tetracycline | 1 (20.0) | 1 (20.0) | 3 (60.0) | |
|
| Ampicillin | 0 (0.0) | 3 (75.0) | 1 (25.0) |
| Trimethoprim/sulfamethoxazole | 2 (50.0) | 1 (25.0) | 0 (0.0) | |
| Ceftriaxone | 4 (100.0) | 0 (0.0) | 0 (0.0) | |
| Streptomycin | 2 (50.0) | 2 (50.0) | 0 (0.0) | |
| Amoxicillin/clavulanic acid | 4 (100.0) | 0 (0.0) | 0 (0.0) | |
| Gentamycin | 4 (100.0) | 0 (0.0) | 0 (0.0) | |
| Kanamycin | 3 (50.0) | 1(25.0) | 0 (0.0) | |
| Ciprofloxacin | 4 (100.0) | 0 (0.0) | 0 (0.0) | |
| Chloramphenicol | 0 (0.0) | 2 (50.0) | 2 (50.0) | |
| Erythromycin | 1 (25.0) | 3 (75.0) | 0 (0.0) | |
| Nalidixic acid | 4 (100.0) | 0 (0.0) | 0 (0.0) | |
| Tetracycline | 0 (0.0) | 1 (25.0) | 3 (75.0) | |